Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.
心衰中的心臟代謝藥物二型鈉葡萄糖轉運蛋白抑製劑和葡萄糖樣肽-1 受體激動劑的保護效應潛在機制。
Int J Mol Sci 2024-03-15
New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review.
利用胰高血糖素樣肽-1受體激動劑(GLP-1 RA)在代謝綜合徵和第2型糖尿病中預防保留射血分數心力衰竭的新機制:一項回顧。
Int J Mol Sci 2024-04-29
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists in the Management of Obesity-Related Heart Failure with Preserved Ejection Fraction: Benefits beyond What Scales Can Measure?
在管理與肥胖相關的保留射出分數心衰竭中,胰高血糖素樣肽-1受體激動劑的新興角色:超越體重秤可測量的益處?
Biomedicines 2024-09-28
Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action.
在不同射血分數保留型心衰竭表現的病理生理背景下,胰高血糖素樣肽-1受體激動劑的潛在益處及作用機制。
Card Fail Rev 2024-11-07
Effect of a Meal on Invasive Hemodynamics and Plasma Incretin Levels in Patients With Heart Failure.
餐食對心臟衰竭患者侵入性血流動力學和血漿胰高血糖素水平的影響。
Circ Heart Fail 2025-04-07
這項研究探討腸胃激素(如GLP-1和GIP)在心臟衰竭中的角色,對象包括14名心臟衰竭患者和10名健康對照者。主要發現有:
1. 心臟衰竭患者餐後心臟指數顯著低於對照組(2.8 vs. 4.0 L/min per m²)。
2. 心臟衰竭患者的GLP-1水平高於對照組,且與中心靜脈壓相關。
3. GIP濃度在兩組間無顯著變化。
4. 患者報告的腸胃症狀較重,消化不良與上腸系膜動脈血流增加有關。
研究顯示腸道激素與心臟衰竭之間存在複雜的相互作用。
PubMedDOI